Vector Science and Therapeutics Corp (TSXV:PAIN), a pharmaceutical-grade peptide and precision drug delivery company, announced on Wednesday the appointment of Darryl Drake Jr. as president of Valor, its athlete and performance division, and chairman of the Athletic board.

In this capacity, Drake leads the company's commercial strategy, athlete partnership development, and public-facing mission to bring physician-supervised, FDA-regulated peptide therapeutics to athletes, entertainers, and high-performance individuals across the United States and internationally.

According to the company, Drake brings to Vector a career built at the intersection of leadership, capital formation, network development, and early-stage business growth. He has raised significant capital, built institutional relationships, and created athlete partnerships from the ground up. His ability to translate complex scientific innovation into culturally resonant communication was the central reason Valor was established.